

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS



PHM119A
January 2013

Mary Anne Crandall
Project Analyst

ISBN: 0-89336-179-8

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR STUDY	1
SCOPE OF STUDY	1
METHODOLOGY AND INFORMATION SOURCES	1
ANALYST CREDENTIALS	2
RELATED BCC REPORTS	2
BCC ON-LINE SERVICES	2
DISCLAIMER	3
CHAPTER 2 EXECUTIVE SUMMARY	5
<i>SUMMARY TABLE TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	5
<i>SUMMARY FIGURE TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)</i>	6
CHAPTER 3 INDUSTRY OVERVIEW	8
THE CIRCULATORY SYSTEM	8
BLOOD VESSEL STRUCTURE	8
BLOOD FLOW	9
CONDITIONS	10
THROMBUS	10
EMBOLUS	11
ALTERATIONS IN VENOUS FLOW	11
DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM	12
<i>TABLE 1 FACTORS PREDISPOSING TO PULMONARY EMBOLISM OF VIRCHOW'S TRIAD</i>	13
HEMOSTASIS (THE CLOTTING PROCESS)	13
DISEASES ASSOCIATED WITH THROMBOEMBOLISM	14
ACUTE CORONARY SYNDROME	15
Ischemic Heart Disease	15
Etiology	15
Mechanisms of Coronary Atherosclerosis	15
Pathophysiology of Ischemia	16
ANGINA PECTORIS	17
ACUTE ISCHEMIA AND MYOCARDIAL INFARCTION	17
CHRONIC ISCHEMIC CARDIOMYOPATHY	18
SUDDEN CARDIAC DEATH	18
ATRIAL FIBRILLATION	18
Causes	19
CEREBROVASCULAR DISEASE	19
Peripheral Artery Disease (PAD)	20
Prevalence and Incidence	20
Symptoms	21
Causes	21
STENTS AND THROMBOSIS	21
DEMOGRAPHICS	22

TOPIC	PAGE NO.
<i>TABLE 2 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050</i>	23
<i>FIGURE 1 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050 (MILLIONS)</i>	23
CARDIOVASCULAR, VTE, ATRIAL FIBRILLATION AND STROKE DEMOGRAPHICS	24
Venous Thromboembolism	24
Cardiovascular Disease	25
<i>TABLE 3 HEART DISEASE DEATHS BY COUNTRY</i>	26
Stroke	26
<i>TABLE 4 U.S. STROKE DEMOGRAPHICS BY SELECTED CHARACTERISTICS, 2010 (THOUSANDS)</i>	27
Atrial Fibrillation	28
VENOUS THROMBOEMBOLISM AND LIFESTYLE	28
VENOUS THROMBOEMBOLISM AND AIR TRAVEL	28
CHAPTER 4 ANTICOAGULANTS	31
OVERVIEW	31
PARENTERAL	31
PRODUCTS	32
LOW MOLECULAR WEIGHT HEPARINS	32
Lovenox	32
Fragmin	32
Innohep	33
Orgaran and Normiflo	33
Embolex	33
Fraxiparine	33
Ariven/Arteven	33
ORAL ANTICOAGULANTS - VITAMIN K ANTAGONISTS	33
GLOBAL MARKET SIZE AND GROWTH	34
<i>TABLE 5 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	35
<i>FIGURE 2 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)</i>	35
GROWTH BY GEOGRAPHIC REGION	35
<i>TABLE 6 GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2012 (%)</i>	36
<i>FIGURE 3 GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2012 (%)</i>	36
<i>TABLE 7 FORECAST GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2017 (%)</i>	37
<i>FIGURE 4 FORECAST GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2017 (%)</i>	37
GROWTH BY DRUG TYPE	37
<i>TABLE 8 GLOBAL MARKET SIZE OF ANTICOAGULANT DRUG REVENUES BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)</i>	38
<i>FIGURE 5 GLOBAL MARKET SIZE OF ANTICOAGULANT DRUG REVENUE BY DRUG TYPE, 2011-2017 (\$ MILLIONS)</i>	38
<i>TABLE 9 GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012 (%)</i>	39
<i>FIGURE 6 GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012 (%)</i>	39
<i>TABLE 10 GLOBAL ANTICOAGULANT DRUG BY DRUG TYPE, 2017 (%)</i>	39
<i>FIGURE 7 GLOBAL ANTICOAGULANT MARKET BY DRUG TYPE, 2017 (%)</i>	39

TOPIC	PAGE NO.
COMPETITIVE ANALYSIS	40
<i>TABLE 11 TOTAL GLOBAL ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)</i>	40
<i>FIGURE 8 TOTAL GLOBAL ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)</i>	40
<i>TABLE 12 TOTAL GLOBAL ANTICOAGULANT DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE</i>	41
CHAPTER 5 ANTIPLATELETS	43
OVERVIEW	43
PRODUCTS	43
ORAL ANTIPLATELETS	43
Plavix	43
Pletal	43
Effient	43
Ticlid	44
Brilinta	44
IV ANTIPLATELETS	44
Integrilin	44
Aggrastat	44
ReoPro	44
GLOBAL MARKET SIZE AND GROWTH	44
<i>TABLE 13 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTIPLATELET DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	45
<i>FIGURE 9 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTIPLATELET DRUGS, 2011-2017 (\$ MILLIONS)</i>	45
GROWTH BY GEOGRAPHIC REGION	46
<i>TABLE 14 TOTAL GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2012 (%)</i>	46
<i>FIGURE 10 TOTAL GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2012 (%)</i>	46
<i>TABLE 15 FORECAST GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2017 (%)</i>	47
<i>FIGURE 11 FORECAST GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2017 (%)</i>	47
GROWTH BY DRUG TYPE	48
<i>TABLE 16 GLOBAL MARKET SIZE OF ANTIPLATELET DRUG REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)</i>	48
<i>FIGURE 12 GLOBAL MARKET SIZE OF ANTIPLATELET DRUG REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)</i>	48
<i>TABLE 17 GLOBAL ANTIPLATELET DRUG MARKET BY DRUG TYPE, 2012 (%)</i>	49
<i>FIGURE 13 GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012 (%)</i>	49
<i>TABLE 18 GLOBAL ANTIPLATELET MARKET BY DRUG TYPE, 2017 (%)</i>	50
<i>FIGURE 14 GLOBAL ANTIPLATELET MARKET BY DRUG TYPE, 2017 (%)</i>	50
COMPETITIVE ANALYSIS	51
<i>TABLE 19 TOTAL GLOBAL ANTIPLATELET DRUG MARKET COMPETITIVE ANALYSIS, 2012 (\$ MILLIONS/%)</i>	51
<i>FIGURE 15 TOTAL GLOBAL ANTIPLATELET DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)</i>	51

TOPIC	PAGE NO.
<i>TABLE 20 GLOBAL ANTIPLATELET DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE</i>	52
CHAPTER 6 THROMBIN INHIBITORS	54
OVERVIEW	54
PRODUCTS	54
DIRECT THROMBIN INHIBITORS	54
Argatroban	54
Angiomax	54
Iprivask	54
Pradaxa	54
THROMBOLYTIC AGENTS	55
Thrombolytic Enzymes	55
Tissue Plasminogen Activators	55
Activase	55
Retavase	56
TNKase	56
ATryn	56
DIRECT FACTOR XA INHIBITORS	56
Xarelto	56
Betrixaban	57
Edoxaban	57
Eliquis	57
GLOBAL THROMBIN INHIBITOR MARKET SIZE AND GROWTH	57
<i>TABLE 21 PROJECTED GLOBAL MARKET SIZE AND GROWTH BY REGION FOR THROMBIN INHIBITORS, THROUGH 2017 (\$ MILLIONS)</i>	58
<i>FIGURE 16 PROJECTED GLOBAL MARKET SIZE AND GROWTH BY REGION FOR THROMBIN INHIBITORS, 2011-2017 (%)</i>	58
THROMBIN INHIBITOR GROWTH BY GEOGRAPHIC REGION	59
<i>TABLE 22 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2012 (%)</i>	59
<i>FIGURE 17 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2012 (%)</i>	59
<i>TABLE 23 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2017 (%)</i>	60
<i>FIGURE 18 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2017 (%)</i>	60
GROWTH BY DRUG TYPE	60
<i>TABLE 24 GLOBAL THROMBIN INHIBITOR MARKET REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)</i>	61
<i>FIGURE 19 GLOBAL THROMBIN INHIBITOR MARKET REVENUE BY DRUG TYPE, 2011-2017 (\$ MILLIONS)</i>	61
<i>TABLE 25 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2012 (%)</i>	62
<i>FIGURE 20 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2012 (%)</i>	62
<i>TABLE 26 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2017 (%)</i>	63
<i>FIGURE 21 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2017 (%)</i>	63
COMPETITIVE ANALYSIS	63
<i>TABLE 27 TOTAL GLOBAL THROMBIN INHIBITOR DRUG MARKET COMPETITIVE ANALYSIS, 2012 (\$ MILLIONS/%)</i>	64

TOPIC	PAGE NO.
<i>FIGURE 22 TOTAL GLOBAL THROMBIN INHIBITOR DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)</i>	64
<i>TABLE 28 TOTAL GLOBAL THROMBIN INHIBITOR DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE</i>	64
RESEARCH AND DEVELOPMENT	65
<i>TABLE 29 ANTITHROMBOTIC/ANTICOAGULANT TREATMENTS IN DEVELOPMENT, 2012</i>	67
TOTAL MARKET ANALYSIS	68
OVERVIEW	68
GLOBAL MARKET SIZE AND GROWTH	68
<i>TABLE 30 SIZE OF GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)</i>	69
<i>FIGURE 23 SIZE OF GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET REVENUE BY DRUG TYPE, 2011-2017 (\$ MILLIONS)</i>	69
<i>TABLE 31 GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE, 2012 (%)</i>	70
<i>FIGURE 24 GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE, 2012 (%)</i>	70
<i>TABLE 32 FORECAST GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE 2017 (%)</i>	71
<i>FIGURE 25 FORECAST GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY DRUG TYPE, 2017 (%)</i>	71
GROWTH BY GEOGRAPHIC REGION	72
<i>TABLE 33 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	72
<i>FIGURE 26 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)</i>	72
<i>TABLE 34 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY GEOGRAPHIC REGION, 2012 (%)</i>	73
<i>FIGURE 27 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY GEOGRAPHIC REGION, 2012 (%)</i>	73
<i>TABLE 35 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT BY GEOGRAPHIC REGION, 2017 (%)</i>	74
<i>FIGURE 28 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY DRUG TYPE, 2017 (%)</i>	74
COMPETITIVE ANALYSIS	74
<i>TABLE 36 GLOBAL ANTITHROMBIN/ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (\$ MILLIONS/%)</i>	75
<i>FIGURE 29 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)</i>	75
<i>TABLE 37 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE</i>	76
CHAPTER 7 COMPANY PROFILES	78
ABBOTT LABORATORIES	78
ARMETHEON INC.	79
ASTRAZENECA	80
BAXTER INTERNATIONAL	81
BAYER AG	82
BIOVASCULAR, INC.	84
BOEHRINGER INGELHEIM GMBH	84
BRISTOL-MYERS SQUIBB COMPANY	85
CANYON PHARMACEUTICALS	87
CORNERSTONE THERAPEUTICS, INC.	87
CSL BEHRING	88

TOPIC	PAGE NO.
DAIICHI SANKYO COMPANY LTD	89
EISAI COMPANY, LTD.	90
ELI LILLY	91
EMISPHERE TECHNOLOGIES	92
GENENTECH	93
GLAXOSMITHKLINE	94
GTC BIOTHERAPEUTICS	95
JOHNSON & JOHNSON	95
LIGAND PHARMACEUTICALS, INC.	96
MERCK	97
MERRION PHARMACEUTICALS, LTD.	98
MICROBIX BIOSYSTEMS, INC.	99
NOVARTIS	100
ONO PHARMACEUTICAL CO., LTD	101
OTSUKA PHARMACEUTICAL CO., LTD.	101
PFIZER, INC	102
PORTOLA PHARMACEUTICALS	104
REGADO	104
SANOFI	105
SANTA CRUZ BIOTECHNOLOGY, INC.	107
SERVIER	108
THE MEDICINES COMPANY	108
CHAPTER 8 A COMPLETE LISTING OF ALL THE COMPANIES IN THE REPORT	111

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)	5
TABLE 1 FACTORS PREDISPOSING TO PULMONARY EMBOLISM OF VIRCHOW'S TRIAD	13
TABLE 2 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050	23
TABLE 3 HEART DISEASE DEATHS BY COUNTRY	26
TABLE 4 U.S. STROKE DEMOGRAPHICS BY SELECTED CHARACTERISTICS, 2010 (THOUSANDS)	27
TABLE 5 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)	35
TABLE 6 GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2012 (%)	36
TABLE 7 FORECAST GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2017 (%)	37
TABLE 8 GLOBAL MARKET SIZE OF ANTICOAGULANT DRUG REVENUES BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)	38
TABLE 9 GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012 (%)	39
TABLE 10 GLOBAL ANTICOAGULANT DRUG BY DRUG TYPE, 2017 (%)	39
TABLE 11 TOTAL GLOBAL ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)	40
TABLE 12 TOTAL GLOBAL ANTICOAGULANT DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE	41
TABLE 13 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTIPLATELET DRUGS, THROUGH 2017 (\$ MILLIONS)	45
TABLE 14 TOTAL GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2012 (%)	46
TABLE 15 FORECAST GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2017 (%)	47
TABLE 16 GLOBAL MARKET SIZE OF ANTIPLATELET DRUG REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)	48
TABLE 17 GLOBAL ANTIPLATELET DRUG MARKET BY DRUG TYPE, 2012 (%)	49
TABLE 18 GLOBAL ANTIPLATELET MARKET BY DRUG TYPE, 2017 (%)	50
TABLE 19 TOTAL GLOBAL ANTIPLATELET DRUG MARKET COMPETITIVE ANALYSIS, 2012 (\$ MILLIONS/%)	51
TABLE 20 GLOBAL ANTIPLATELET DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE	52
TABLE 21 PROJECTED GLOBAL MARKET SIZE AND GROWTH BY REGION FOR THROMBIN INHIBITORS, THROUGH 2017 (\$ MILLIONS)	58
TABLE 22 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2012 (%)	59
TABLE 23 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2017 (%)	60
TABLE 24 GLOBAL THROMBIN INHIBITOR MARKET REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)	61
TABLE 25 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2012 (%)	62
TABLE 26 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2017 (%)	63
TABLE 27 TOTAL GLOBAL THROMBIN INHIBITOR DRUG MARKET COMPETITIVE ANALYSIS, 2012 (\$ MILLIONS/%)	64
TABLE 28 TOTAL GLOBAL THROMBIN INHIBITOR DRUG MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE	64
TABLE 29 ANTITHROMBOTIC/ANTICOAGULANT TREATMENTS IN DEVELOPMENT, 2012	67
TABLE 30 SIZE OF GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)	69
TABLE 31 GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE, 2012 (%)	70

TABLE HEADING	PAGE NO.
TABLE 32 FORECAST GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE 2017 (%)	71
TABLE 33 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, THROUGH 2017 (\$ MILLIONS)	72
TABLE 34 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY GEOGRAPHIC REGION, 2012 (%)	73
TABLE 35 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT BY GEOGRAPHIC REGION, 2017 (%)	74
TABLE 36 GLOBAL ANTITHROMBIN/ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (\$ MILLIONS/%)	75
TABLE 37 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MANUFACTURER PRODUCT PARTICIPATION BY DRUG TYPE	76

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)	6
FIGURE 1 TOTAL GLOBAL POPULATION BY SELECTED GEOGRAPHICAL REGION, 2000 TO 2050 (MILLIONS)	23
FIGURE 2 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)	35
FIGURE 3 GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2012 (%)	36
FIGURE 4 FORECAST GLOBAL MARKET FOR ANTICOAGULANT DRUG REVENUES BY REGION, 2017 (%)	37
FIGURE 5 GLOBAL MARKET SIZE OF ANTICOAGULANT DRUG REVENUE BY DRUG TYPE, 2011-2017 (\$ MILLIONS)	38
FIGURE 6 GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012 (%)	39
FIGURE 7 GLOBAL ANTICOAGULANT MARKET BY DRUG TYPE, 2017 (%)	39
FIGURE 8 TOTAL GLOBAL ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)	40
FIGURE 9 TOTAL GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTIPLATELET DRUGS, 2011-2017 (\$ MILLIONS)	45
FIGURE 10 TOTAL GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2012 (%)	46
FIGURE 11 FORECAST GLOBAL MARKET FOR ANTIPLATELET DRUG REVENUES BY REGION, 2017 (%)	47
FIGURE 12 GLOBAL MARKET SIZE OF ANTIPLATELET DRUG REVENUE BY DRUG TYPE, THROUGH 2017 (\$ MILLIONS)	48
FIGURE 13 GLOBAL ANTICOAGULANT DRUG MARKET BY DRUG TYPE, 2012 (%)	49
FIGURE 14 GLOBAL ANTIPLATELET MARKET BY DRUG TYPE, 2017 (%)	50
FIGURE 15 TOTAL GLOBAL ANTIPLATELET DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)	51
FIGURE 16 PROJECTED GLOBAL MARKET SIZE AND GROWTH BY REGION FOR THROMBIN INHIBITORS, 2011-2017 (%)	58
FIGURE 17 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2012 (%)	59
FIGURE 18 TOTAL GLOBAL MARKET FOR THROMBIN INHIBITOR DRUG REVENUES BY REGION, 2017 (%)	60
FIGURE 19 GLOBAL THROMBIN INHIBITOR MARKET REVENUE BY DRUG TYPE, 2011-2017 (\$ MILLIONS)	61
FIGURE 20 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2012 (%)	62
FIGURE 21 GLOBAL THROMBIN INHIBITOR MARKET BY DRUG TYPE, 2017 (%)	63
FIGURE 22 TOTAL GLOBAL THROMBIN INHIBITOR DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)	64
FIGURE 23 SIZE OF GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET REVENUE BY DRUG TYPE, 2011-2017 (\$ MILLIONS)	69
FIGURE 24 GLOBAL ANTITHROMBIN/ANTICOAGULANT MARKET BY DRUG TYPE, 2012 (%)	70
FIGURE 25 FORECAST GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY DRUG TYPE, 2017 (%)	71
FIGURE 26 GLOBAL MARKET SIZE AND GROWTH BY REGION FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2011-2017 (\$ MILLIONS)	72
FIGURE 27 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY GEOGRAPHIC REGION, 2012 (%)	73
FIGURE 28 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT MARKET BY DRUG TYPE, 2017 (%)	74
FIGURE 29 GLOBAL ANTITHROMBOTIC/ANTICOAGULANT DRUG MARKET COMPETITIVE ANALYSIS, 2012 (%)	75